Every year approximately 1.5 million prostheses are implanted worldwide for breast augmentation and reconstructive indications. 1 The history of implant-based breast reconstruction spans three centuries with the first report of successful breast augmentation in 1895, in which Czerny 2 described transplanting a lipoma from the trunk to the breast in a patient deformed by a partial mastectomy. In 1889, Gersuny attempted breast reconstruction with paraffin injections although with disastrous results. 3 In the first half of the 20th century, surgeons employed other materials and prostheses as breast fillers and implants, respectively, such as ivory, glass balls, ground rubber, ox cartilage, Terylene wool, gutta-percha […]. 4 During the 1950s and 1960s, breast augmentation with solid alloplastic materials was performed using polyurethane, polytetrafluoroethylene (Teflon), and expanded polyvinyl alcohol formaldehyde (Ivalon sponge). 5 However, the use of these materials was discontinued after patients developed local tissue reactions, firmness, distortion of the breast, and significant discomfort. 6 In 1961, Uchida reported the injection of liquid silicone (polydimethylsiloxane [PDMS]) for breast augmentation. 6 Various other solid and semisolid materials have been injected directly into the breast parenchyma for augmentation, including epoxy resin, shellac, beeswax, paraffin, and petroleum jelly. 7 These techniques resulted in frequent complications, including recurrent infections, chronic inflammation, drainage, granuloma formation, and even necrosis. 8 Breast augmentation by injection of free liquid silicone and